ANTIPHOSPHOLIPID ANTIBODIES

Size: px
Start display at page:

Download "ANTIPHOSPHOLIPID ANTIBODIES"

Transcription

1 CLINICAL REVIEW CLINICIAN S CORNER Management of Antiphospholipid Antibody Syndrome A Systematic Review Wendy Lim, MD Mark A. Crowther, MD John W. Eikelboom, MBBS ANTIPHOSPHOLIPID ANTIBODIES were first described in 1906 in a study by Wassermann et al 1 among patients with positive serologic test results for syphilis. Antiphospholipid antibodies are a heterogeneous group of autoantibodies directed against phospholipidbinding proteins. Antiphospholipid antibodies can be broadly categorized into those antibodies that prolong phospholipid-dependent coagulation assays, known as lupus anticoagulants (LA), or anticardiolipin antibodies (acl), which target a molecular congener of cardiolipin (a bovine cardiac protein). The presence of these antibodies in patients with arterial or venous thrombosis or pregnancy morbidity comprises the antiphospholipid antibody syndrome (APS). This syndrome is referred to as primary APS when it occurs alone and secondary APS when it occurs in association with other conditions, such as systemic lupus erythematosus (SLE). Antiphospholipid antibodies are also found in patients with infections such as human immunodeficiency virus 2 and may develop during therapy with medications such as chlorpromazine. 3,4 Their clinical importance in these settings is unknown. The CME available online at Context Antiphospholipid antibodies are autoantibodies directed against proteins that bind to phospholipid. Antiphospholipid antibody syndrome (APS) refers to the association between antiphospholipid antibodies and thrombosis risk or pregnancy morbidity. Patients with APS may be at increased risk of recurrent arterial or venous thrombosis or pregnancy loss. Objective To systematically review the evidence for treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. Evidence Acquisition Search of MEDLINE (1966 to November 2005) and Cochrane Library electronic databases (2005) and reference lists for randomized trials, metaanalyses of randomized trials, and prospective cohort studies of the treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. Studies were selected on the basis of clinical relevance. Evidence Synthesis Among patients with antiphospholipid antibodies, the absolute risk of developing new thrombosis is low ( 1% per year) in otherwise healthy patients without prior thrombotic events, may be moderately increased (up to 10% per year) in women with recurrent fetal loss without prior thrombosis, and is highest ( 10% in the first year) in patients with a history of venous thrombosis who have discontinued anticoagulant drugs within 6 months. Compared with placebo or untreated control, anticoagulation with moderate-intensity warfarin (adjusted to a target international normalized ratio [INR] of ) reduces the risk of recurrent venous thrombosis by 80% to 90% irrespective of the presence of antiphospholipid antibodies and may be effective for preventing recurrent arterial thrombosis. No evidence exists that high-intensity warfarin (target INR, 3.0) is more effective than moderate-intensity warfarin. For patients with a single positive antiphospholipid antibody test result and prior stroke, aspirin and moderate-intensity warfarin appear equally effective for preventing recurrent stroke. Treatment issues that have not been addressed in clinical trials, or for which the evidence is conflicting, include the role of antithrombotic prophylaxis in patients with antiphospholipid antibodies without prior thrombosis, the optimal treatment of noncerebrovascular arterial thrombosis, recurrent thrombosis despite warfarin therapy, and treatment of women with antiphospholipid antibodies and recurrent fetal loss. Conclusions In patients with APS, moderate-intensity warfarin is effective for preventing recurrent venous thrombosis and perhaps also arterial thrombosis. Aspirin appears to be as effective as moderate-intensity warfarin for preventing recurrent stroke in patients with prior stroke and a single positive test result for antiphospholipid antibody. The optimal treatment of other thrombotic aspects of APS needs to be addressed in well-designed prospective studies. JAMA. 2006;295: wwww.jama.com Author Affiliations: Department of Medicine, McMaster University, Hamilton, Ontario. Corresponding Author: John W. Eikelboom, MBBS, Department of Medicine, McMaster University, Hamilton General Hospital McMaster Clinic, 237 Barton St E, Hamilton, Ontario, Canada L9K 1H8 (eikelbj@mcmaster.ca). Clinical Review Section Editor: Michael S. Lauer, MD. We encourage authors to submit papers for consideration as a Clinical Review. Please contact Michael S. Lauer, MD, at lauerm@ccf.org JAMA, March 1, 2006 Vol 295, No. 9 (Reprinted) 2006 American Medical Association. All rights reserved.

2 Sapporo criteria are a widely used consensus definition of APS. 5 Treatment of antiphospholipid antibodies is problematic because of a lack of laboratory standardization, limited data on their natural history, and a lack of randomized treatment trials. Depending on the assay, antiphospholipid antibodies are reported in up to 10% of healthy individuals and in 30% to 50% of patients with SLE. 6 Antiphospholipid antibodies are more common in patients with thrombosis but a causal association is unproven and the clinical relevance of transient or low titer antiphospholipid antibodies remains uncertain. Furthermore, a recent systematic review has questioned the association between isolated acl and thrombosis. 7 We systematically reviewed laboratory testing, diagnostic criteria, and treatment of thrombosis in patients with antiphospholipid antibodies. We reviewed the management of antiphospholipid antibody associated recurrent fetal loss but did not address preconception anticoagulation. The treatment of patients who are pregnant and develop thrombotic complications is the same irrespective of the presence of antiphospholipid antibodies and is addressed in comprehensive reviews and guidelines. 8,9 We did not consider the treatment of antiphospholipid antibody associated thrombocytopenia or catastrophic APS. EVIDENCE ACQUISITION We searched MEDLINE (1966 to November 2005), The Cochrane Library (2005, Issue 4), and The Cochrane Pregnancy and Childbirth Group (The Cochrane Library 2005, Issue 2) databases using the following terms singly and in combination: antiphospholipid (antibody) syndrome, antiphospholipid antibody, lupus anticoagulant, anticardiolipin antibody, thrombosis,(deep) venous thrombosis, pulmonary embolism, arterial thrombosis, arterial occlusive disease, cerebrovascular disorders, stroke, myocardial infarction, anticoagulants, platelet aggregation inhibitors, warfarin, antiplatelet, aspirin, incidence, prevalence, pregnancy, and pregnancy loss. We further reviewed reference lists and articles from the authors libraries. We based our recommendations concerning laboratory testing and diagnosis of APS on published international consensus guidelines. In evaluating thrombosis treatment, we focused on randomized controlled trials or metaanalyses of randomized controlled trials. If these trials were not available, prospective studies were examined before retrospective studies. EVIDENCE SYNTHESIS Laboratory Detection of Antiphospholipid Antibodies Laboratory testing for antiphospholipid antibodies is complicated because there is uncertainty about their antigenic target. Both LA and acl may demonstrate specificity for 2 -glycoprotein I, 10,11 but many other antigenic targets have been described including prothrombin 12 and annexin V. 13 In some cases, antibodies directed against 2 -glycoprotein I rather than anionic phospholipids are believed causal in this syndrome. 14 Consensus guidelines describing laboratory techniques for measuring acl and LA have been published. 15,16 Lupus Anticoagulants Lupus anticoagulants, also referred to as nonspecific inhibitors, are antibodies that block phospholipid surfaces important for coagulation. They reduce the coagulant potential of the plasma and prolong the clotting time in coagulation tests based on the activated partial thromboplastin time. 17 Failure of the prolonged clotting time to correct after a 1:1 mix with normal platelet-free plasma and correction of the clotting time after addition of excess phospholipids confirms the presence of LA. 18 Consensus guidelines recommend screening for LA with 2 or more phospholipid-dependent coagulation tests, including the activated partial thromboplastin time, dilute Russell viper venom time, kaolin clotting time, dilute prothrombin time, textarin time, or taipan time. 18 Anticoagulant therapy may interfere with the detection of LA. 19 Anticardiolipin Antibodies Anticardiolipin antibodies share a common in vitro binding affinity for cardiolipin and can be detected using enzyme-linked immunosorbent assays. The immunoglobulin isotype may be IgG, IgM, or IgA. It is widely believed that the IgG isotype is most strongly associated with thrombosis, although this has not been tested in large prospective studies. 20 Enzyme-linked immunosorbent assay tests for acl are poorly standardized and acl testing has shown poor concordance between laboratories. 17 Anticardiolipin antibodies are reported as a titer specific to the isotype (IgG, IgM, or IgA phospholipid antibody titer), but because the accuracy and reliability of assays are limited, consensus guidelines recommend semiquantitative reporting of results (low, medium, or high titer). 21 Anti 2 -Glycoprotein I Antibodies Anti- 2 glycoprotein I antibodies 22,23 are currently not included in the Sapporo criteria but may be incorporated in future updates. The laboratory assay for these antibodies is not standardized, making comparison between studies difficult. 11 The clinical relevance of anti 2 -glycoprotein I antibodies also is uncertain, although there is some evidence that these antibodies are more specific for APS. 24 Diagnostic Criteria for APS According to the Sapporo criteria, APS is present in patients with 1 clinical and 1 laboratory criterion. Clinical criteria include objectively confirmed arterial, venous, or small-vessel thrombosis, or pregnancy morbidity consisting of recurrent fetal loss before the 10th week of gestation, 1 or more unexplained fetal death at or beyond the 10th week of gestation, or premature birth due to placental insufficiency, eclampsia, or preeclampsia. Laboratory criteria include medium or high titer IgG or IgM acl or the presence of LA on 2 or more occasions at least 6 weeks apart. 15,16 Although consensus-derived diagnostic criteria such as those formu American Medical Association. All rights reserved. (Reprinted) JAMA, March 1, 2006 Vol 295, No

3 lated by the Sapporo international workshop require repeated measurement to establish a diagnosis of APS, there is no evidence that transient antiphospholipid antibodies are less important than persistent antibodies. Two of the largest studies to examine the prognostic importance of antiphospholipid antibodies tested patients on only one occasion: at the time of presentation with stroke 25 and 6 months following the diagnosis of venous thromboembolism. 26 Association of Antiphospholipid Antibodies and Thrombosis Cross-sectional studies among healthy blood donors report LA in 8% of patients, 27 IgG acl in 6.5% of patients, and IgM acl in 9.4% of patients. 28 Persistently positive antiphospholipid antibodies are unusual in healthy individuals ( 2% of healthy blood donors initially found to have acl still had increased levels 9 months later). 28 In a general obstetric population, the prevalence of LA was 0.3% and the prevalence of acl was 2.2% to 9.1%, which was similar to that observed among patients who are not pregnant (5.6%). 29,30 In comparison, the prevalence of antiphospholipid antibodies appears to be higher, in the range of 4% to 21%, among patients presenting with thrombosis. 31,32 The increased prevalence of antiphospholipid antibodies among patients with thrombosis suggests an association between antiphospholipid antibodies and thrombosis, and the increasing risk of thrombosis among those patients with increasing antibody titers further strengthens the evidence that the association is causal. However, there remains controversy about the true nature of this relationship, which may also be confounded by the presence of unmeasured LA. 33 The association between antiphospholipid antibodies and thrombosis is stronger with LA than with acl. In a meta-analysis of 25 studies involving more than 7000 patients, the mean odds ratio (OR) for thrombosis was 1.6 for acl and 11.0 for LA, 7 which is consistent with the results of an earlier metaanalysis of 6 studies. 34 However, these meta-analyses are limited by the quality of the included studies; there are no large prospective studies of unselected patients whose antiphospholipid antibody status was determined before objective documentation of thrombotic complications. In the Framingham Heart Study cohort, increased acl was independently associated with an increased risk of ischemic stroke or transient ischemic attack in women (hazard ratio [HR], 2.6; absolute risk, 3.2%) but not in men (HR, 1.3; absolute risk, 4.5%). 35 Thrombosis is presumed to cause many of the pregnancy complications associated with APS. In women without SLE, a retrospective review of more than patients found a prevalence of antiphospholipid antibodies of 20% among women with recurrent fetal loss compared with 5% in healthy women. 36 The association between antiphospholipid antibodies and fetal loss is strongest for loss occurring after 10 weeks. 37 The association between antiphospholipid antibodies and the risk of premature birth due to eclampsia or preeclampsia and intrauterine growth restriction remains controversial; studies contributing data to this area tend to be small, retrospective, and have conflicting results. 38,39 Furthermore, the toxicity of treatments evaluated in these studies may contribute to pregnancy loss or complication and may confound the association between antiphospholipid antibodies and adverse pregnancy outcomes. 40 Determining Thrombosis Risk in APS The optimal treatment of thrombosis risk in patients with APS requires assessment of thrombosis risk associated with antiphospholipid antibodies so that the potential benefits of antithrombotic therapies for preventing thrombosis can be balanced against the risk of bleeding. Patients Without Prior Thrombosis. In patients with SLE, the incidence of thrombosis was 2 per 100 personyears in a prospective cohort of 551 patients of whom 49% had either LA or acl. 41 The OR of thrombosis was 3.20 (95% confidence interval [CI], ) for LA and 6.80 (95% CI, ) for high-titer acl. However, patients with SLE have a high prevalence of thrombosis even in the absence of antiphospholipid antibodies 6 and there are only limited data describing the risk of thrombosis in patients with an isolated antiphospholipid antibody who do not have SLE. Among 552 randomly selected blood donors, no thrombotic events were observed after 12 months of follow-up among patients found to have acl. 28 Consequently, the risk of thrombosis among healthy patients who are incidentally found to have an antiphospholipid antibody is likely to be low ( 1% per year). The risk of fetal loss and premature birth among asymptomatic women who have antiphospholipid antibodies appears to be increased, based on studies comparing the rates of these outcomes in women considered to be at low risk of pregnancy loss with and without antiphospholipid antibodies. 29,42-44 Comparison of these studies is complicated by differences in the definition of pregnancy loss and the timing of testing for antiphospholipid antibodies. Nevertheless, each of the studies demonstrated a lower livebirth rate in women with antiphospholipid antibodies, ranging from 62% to 84% compared with 90% to 98% in women without these antibodies. Patients With Fetal Loss but No Prior Thrombosis. The risk of thrombosis among women with antiphospholipid antibodies and fetal loss may be increased, based on the results of a retrospective study comparing aspirin with no prophylaxis in 65 nonpregnant women with antiphospholipid antibodies and a history of pregnancy loss. 45 During a mean (SD) duration of 8.1 (3.5) years, 20 (59%) of 34 patients who were not treated experienced venous or arterial thrombosis (7.4 per 100 patient-years) compared with a background risk of thrombosis of approximately 1 per per year in unselected premenopausal women JAMA, March 1, 2006 Vol 295, No. 9 (Reprinted) 2006 American Medical Association. All rights reserved.

4 Patients With Prior Thrombosis. The risk of recurrent thrombosis among patients with antiphospholipid antibodies is based on limited retrospective studies of untreated patients or studies of patients followed up prospectively after their anticoagulant drugs have been discontinued. 47 Three prospective studies suggest that there is an increased risk of recurrence, ranging from 10% to 67% per year. 26,48,49 In a large prospective study, patients with a first episode of venous thromboembolism who completed 6 months of anticoagulation were tested for acl and followed up prospectively after anticoagulant drugs were discontinued. After 4 years, 20 (29%) of 68 patients with increased acl had recurrent thrombosis compared with 47 (14%) of 334 patients without acl (risk ratio, 2.1; 95% CI, ). 26 Most patients included in these studies did not conform to the consensus definition for APS because antiphospholipid antibody testing was performed only once and testing was often performed after recurrence. In patients who received no antithrombotic treatment, retrospective studies report recurrence rates of 0.19 events 50 or 0.29 events per year of follow-up. 51 These studies report recurrent thrombosis in 52% to 69% of patients during 5 to 6 years of followup, regardless of the type of antithrombotic therapy. 50,51 The incidence of thrombosis was highest during the first 6 months following discontinuation of warfarin therapy, with an event rate of 1.30 events per year of follow-up. 51 Recurrent thrombosis in APS tends to occur in the same vascular distribution as the original event. Patients with venous thrombosis generally have recurrent venous events and patients with arterial thrombosis have recurrent arterial events. 50,52 Risk of Bleeding. Estimates of bleeding risk are derived from studies evaluating anticoagulant therapy in patients with APS. Major bleeding occurs at a frequency of 2% to 3% per year, which is comparable with the bleeding rates observed in patients without APS but who receive anticoagulant therapy. 53,54 Patients with antiphospholipid antibodies directed against prothrombin may rarely present with a bleeding diathesis. 55 Antithrombotic Treatment of APS A proposed treatment algorithm of antithrombotic treatment recommendations and corresponding levels of evidence on which the recommendations are based is shown in the FIGURE. Venous Thromboembolism. Venous thromboembolism is the most common initial clinical manifestation among patients with APS, occurring in 32% of patients who meet consensus conference criteria for the diagnosis. 56 Initial treatment of venous thromboembolism in patients with APS consists of initial unfractionated or lowmolecular-weight heparin for at least 5 days, overlapped with warfarin therapy. 57 Compared with placebo or untreated control, moderate-intensity warfarin (adjusted to a target international normalized ratio [INR] of ) reduces the risk of recurrent venous thrombosis by 80% to 90% irrespective of the presence of antiphospholipid antibodies. 58 For long-term treatment of venous thromboembolism, retrospective case series suggested that high-intensity warfarin (INR, 3.0) was more effective than either aspirin or warfarin administered with a target INR of less than ,51 However, 2 randomized trials 53,54 have shown that high-intensity warfarin is not better than moderate-intensity warfarin (INR, ) in preventing recurrent thrombosis. In the first trial, 53 among 114 patients with APS who were randomized (74% with previous venous thrombosis) and followed up for a mean duration of 2.7 years, the incidence of recurrent thrombosis was 10.7% among patients who received high-intensity warfarin and 3.4% among those who received moderate-intensity warfarin (HR, 3.1; 95% CI, ). Major bleeding rates were comparable in the 2 groups, occurring in 5.4% of patients treated with high-intensity warfarin and 6.9% of patients receiving moderateintensity warfarin (HR, 1.0; 95% CI, ). Overall bleeding rates were also comparable in the 2 groups, occurring in 25% and 19% of patients, respectively (HR, 1.9; 95% CI, ). 53 In the second trial, 54 among 109 patients with APS who were randomized (89% had previous venous thrombosis) and followed up for a median duration of 3.6 years, the incidence of recurrent thrombosis was 11.1% among patients who received high-intensity warfarin and 5.5% among those who received moderate-intensity warfarin (HR, 1.97; 95% CI, ). Bleeding rates were not significantly different in the 2 groups (27.8% vs 14.6%; HR, 2.18; 95% CI, ). 54 Both of these studies were designed to demonstrate that high-intensity warfarin was better than moderateintensity warfarin for prevention of recurrent thrombosis. Neither study was powered to demonstrate equivalence of the 2 interventions. When the results of the 2 studies were combined in a meta-analysis using Peto method, 59 a significant excess of minor bleeding was evident in patients allocated to highintensity warfarin (OR, 2.30; 95% CI, ; P=.02). 54 The pooled data did not demonstrate a significant difference in recurrent thrombosis (highvs moderate-intensity: OR, 2.49; 95% CI, ), total bleeding (OR, 1.73; 95% CI, ), or major bleeding (OR, 0.73; 95% CI, ). The optimal duration of anticoagulation for prevention of recurrent thrombosis in patients with antiphospholipid antibodies is unknown. The risk of recurrence appears to be highest in the 6-month period immediately following discontinuation of anticoagulant drugs but it is unknown whether the absolute risk of recurrence decreases with increasing duration of anticoagulation. In 1 prospective study, patients with a single positive test result for acl who were randomly assigned to stop warfarin after 6 months experienced 23 recurrent events compared with 3 recurrences in 106 patients receiving indefinite anticoagulation (HR, 7.7; 95% CI, ). All patients who experi American Medical Association. All rights reserved. (Reprinted) JAMA, March 1, 2006 Vol 295, No

5 enced recurrent events in the indefinite treatment group had discontinued warfarin before developing recurrent thrombosis. In a second prospective observational study, 48 which measured both LA and acl after presentation with a first episode of venous thromboembolism, the HR for recurrence at 3 months was 4.0 (95% CI, ) for patients who were antiphospholipid antibody positive compared with patients who were antiphospholipid antibody negative. Although these patients received anticoagulant drugs, the incidence of recurrent thrombosis appears to be increased among those with antiphospholipid antibodies compared with those who do not have antiphospholipid antibodies. Prospective studies of patients with APS receiving antithrombotic therapy (mainly warfarin, but also including patients receiving aspirin or no treatment) report an incidence of recurrent thrombosis of 3% to 24% per year. 25,52-54 Retrospective studies report higher recurrence rates, ranging from 53% to 69%. 50,51 Consequently, the general consensus is to treat patients with APS and venous thrombosis with indefinite duration of anticoagulation. 57 Decisions regarding duration of anticoagulation may also be influenced by the type of antiphospholipid antibody (LA vs acl or both) and whether the antibody response is persistent. Because there is a perception that LA compared with acl is more strongly associated with thrombosis, the presence of LA may prompt extended anticoagulation, although this is based on expert opinion only. It is unknown whether Figure. Algorithm for Antithrombotic Treatment of Patients With Antiphospholipid Antibodies Patients With Antiphospholipid Antibodies Yes Prior Thrombosis? No Venous Thrombosis Arterial Thrombosis Yes Pregnant? No First Episode or Recurrent Episode While Not Receiving Warfarin or While the INR Was Below the Target Range Cerebral First Episode or Recurrent Episode While Not Receiving Aspirin or Warfarin or While the INR Was Below the Target Range Noncerebral First Episode or Recurrent Episode While Not Receiving Warfarin or While the INR Was Below the Target Range Consider Prophylactic Unfractionated Heparin or Low-Molecular-Weight Heparin Plus Aspirin, Particularly if Prior Pregnancy Loss B No Treatment or Low-Dose Aspirin C Warfarin (INR, A ) Long-term Treatment Duration B Warfarin (INR, ) or Aspirin A Long-term Treatment Duration B Warfarin C (INR, ) Long-term Treatment Duration C Strength of Evidence A Strong B Moderate C Weak Recurrent Episode While Receiving Warfarin Recurrent Episode While Receiving Warfarin or Aspirin Recurrent Episode While Receiving Warfarin Options C Low-Molecular-Weight Heparin or Unfractionated Heparin or Warfarin With a Higher Target INR or Warfarin Plus Antiplatelet Agent INR indicates international normalized ratio. Circled capital letters indicate strength of evidence supporting treatment recommendations. *Importance of transient antiphospholipid antibodies is uncertain JAMA, March 1, 2006 Vol 295, No. 9 (Reprinted) 2006 American Medical Association. All rights reserved.

6 anticoagulation can be discontinued in patients whose LA testing becomes negative or if the only laboratory finding is a persistent low-titer acl. In conclusion, patients with antiphospholipid antibodies and a first episode of venous thrombosis should be treated with warfarin administered to achieve an INR of 2.0 to 3.0. The optimal duration of anticoagulation is uncertain but based on prospective data suggesting a high rate of recurrence after warfarin discontinuation; indefinite anticoagulation is recommended. Arterial Thromboembolism. Arterial events in the APS most commonly involve the cerebral circulation, with stroke being the initial clinical manifestation in 13% and transient ischemic attack in 7% of patients with APS. 56 The association between APS and other arterial thrombosis, including myocardial infarction, is less certain. 60 Warfarin and aspirin appear to be equivalent for the prevention of thromboembolic complications in patients with a first ischemic stroke and antiphospholipid antibodies. In the Antiphospholipid Antibodies and Stroke Study (APASS), 25 a prospective cohort study within the randomized doubleblind Warfarin Aspirin Recurrent Stroke Study 61 that compared warfarin (INR, ) and aspirin (325 mg/d) for prevention of recurrent stroke or death, patients were classified into 2 groups based on the presence or absence of antiphospholipid antibodies. Among the 1770 patients included in APASS, there was no difference in the risk of thrombotic events in patients treated with warfarin (relative risk [RR], 0.99; 95% CI, ) compared with aspirin (RR, 0.94; 95% CI, ) and no difference in the risk of bleeding. The presence of either LA or acl was not predictive of recurrent thrombotic events, with 24.2% of patients with antiphospholipid antibodies and 24.0% of patients without antiphospholipid antibodies having recurrent events at 2 years (adjusted RR, 0.98; 95% CI, ). Based on the APASS data, patients with first ischemic stroke and a single positive antiphospholipid antibody test result who do not have another indication for anticoagulation may be treated with aspirin (325 mg/d) or moderate-intensity warfarin (INR, ). 62 Aspirin is likely to be preferred because of its ease of use and lack of need for laboratory monitoring. Antithrombotic Treatment of APS in Pregnancy The optimal treatment of pregnant women with antiphospholipid antibodies and 1 or more fetal losses after 10 weeks gestation without thrombosis is controversial. A systematic review 63 of 13 randomized and quasi-randomized trials involving 849 pregnant women with a history of pregnancy loss and antiphospholipid antibodies found that combination therapy with unfractionated heparin (5000 units subcutaneously twice daily) and aspirin (75-81 mg/d) significantly reduced pregnancy loss compared with aspirin alone (RR, 0.46; 95% CI, ). However, this particular comparison was examined in only 2 trials involving 140 patients. 64,65 The combination of lowmolecular-weight heparin (5000 units subcutaneously daily) and aspirin (75 mg/d) compared with aspirin alone did not significantly reduce pregnancy loss (RR, 0.78; 95% CI, ), based on 1 trial of 98 patients. 66 Aspirin (50-81 mg/d) compared with placebo or usual care did not reduce the rate of pregnancy loss in 3 trials (RR, 1.05; 95% CI, ) Low doses of subcutaneous unfractionated heparin (5000 units twice daily) appear to be as effective as high-dose heparin ( units twice daily) (RR, 0.83; 95% CI, ). 64 Consensus recommendations suggest that women with antiphospholipid antibodies and a history of 2 or more early pregnancy losses or 1 or more late pregnancy losses who have no prior history of thrombosis receive treatment with combination aspirin and heparin (unfractionated or lowmolecular-weight) during pregnancy. 8 Aspirin (81 mg/d) should be started with attempted conception and heparin ( units every 12 hours) or low-molecular-weight heparin in prophylactic doses (enoxaparin, 1 mg/kg or mg; dalteparin, 5000 units; or nadroparin, 3800 units, all administered once daily) should be started when a viable intrauterine pregnancy is documented and continued until late in the third trimester. 70 CONTROVERSIES Antithrombotic Prophylaxis in APS The treatment of patients who are incidentally found to have an antiphospholipid antibody and have no prior thrombosis has not been adequately studied, except in patients with SLE. Consensus opinion suggests low-dose aspirin (81 mg/d) may be considered for asymptomatic patients who are not pregnant. 71 Optimal Treatment of First Noncerebral Arterial Thrombosis The optimal treatment of patients who have antiphospholipid antibodies and non central nervous system arterial thrombosis is uncertain. Many patients with myocardial infarction and antiphospholipid antibodies are treated empirically with long-term warfarin therapy administered to achieve an INR of 2.0 to 3.0. Optimal Therapy for Recurrent Thrombosis During Warfarin Treatment Treatment of patients with APS who have recurrent thrombotic events is uncertain. 72 For patients not receiving anticoagulant drugs, immediate initiation of anticoagulation with heparin followed up by long-term warfarin is indicated. Patients with recurrent thrombotic events despite warfarin pose a challenge for clinicians. The INR at the time of recurrence is important; an INR below the target therapeutic range represents inadequate anticoagulation as opposed to warfarin failure. These patients may be treated in the same manner as a patient presenting with new thrombosis without warfarin. Possible treatment options for recurrent 2006 American Medical Association. All rights reserved. (Reprinted) JAMA, March 1, 2006 Vol 295, No

7 thrombosis despite warfarin in the target INR range include increasing the intensity of warfarin anticoagulation to achieve a higher target INR (target INR, or ), switching from warfarin to therapeutic doses of unfractionated heparin or low-molecularweight heparin, or adding an antiplatelet agent to warfarin. Plasma exchange or intravenous immune globulin, particularly in patients with catastrophic APS, have also been suggested. 73 CONCLUSIONS Since initial reports of an association between acl and thrombosis and fetal death, 74 much of the research has focused on the pathogenesis and clinical features of APS. Prospective studies on the optimal treatment of thrombosis in APS have focused primarily on venous thrombosis and ischemic stroke. The results of these studies indicate that patients with antiphospholipid antibodies and venous thrombosis should be treated with longterm (potentially indefinite) anticoagulation with warfarin administered to achieve an INR of 2.0 to 3.0. Either moderate-intensity warfarin or aspirin is acceptable for patients with antiphospholipid antibodies and a first episode of stroke. Prospective studies addressing the issue of primary antithrombotic prophylaxis in asymptomatic patients with antiphospholipid antibodies are in progress. 75,76 These and other well-designed prospective studies are required to complete the understanding of the optimal treatment of patients with antiphospholipid antibodies and APS. Author Contributions: Dr Eikelboom had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Eikelboom. Acquisition of data: Lim, Eikelboom. Analysis and interpretation of data: Lim, Crowther, Eikelboom. Drafting of the manuscript: Lim, Eikelboom. Critical revision of the manuscript for important intellectual content: Crowther, Eikelboom. Study supervision: Eikelboom. Financial Disclosures: None reported. Funding/Support: No funding was received for this review. Dr Lim is the recipient of the International Society on Thrombosis and Haemostasis/Sanofi- Aventis Clinical Research Fellowship. Dr Crowther is a Career Investigator of the Heart and Stroke Foundation of Canada. Dr Eikelboom holds a Tier II Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes of Health Research. REFFERENCES 1. Wassermann A, Neisser A, Bruck C. Eine serodiagnostische Reaction bei Syphilis [German]. Dtsch Med Wochenschr. 1906;32: Gharavi AE, Sammaritano LR, Wen J, et al. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. J Rheumatol. 1994;21: Canoso RT, de Oliveira RM, Nixon RA. Neurolepticassociated autoantibodies: a prevalence study. Biol Psychiatry. 1990;27: Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol. 1990;93: Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42: Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost. 1991; 66: Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101: Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):627s-644s. 9. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost. 2003;1: McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87: Galli M, Luciani D, Bertolini G, Barbui T. Antibeta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102: de Groot PG, Horbach DA, Simmelink MJ, van Oort E, Derksen RH. Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. Lupus. 1998;7(suppl 2):S32-S Satoh A, Suzuki K, Takayama E, et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol. 1999;26: de Groot PG, Derksen RH. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost. 2005; 3: Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations: a cooperative project of the European Antiphospholipid Forum. Thromb Haemost. 2001;86: Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. Thromb Haemost. 1995;74: Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med. 2002;126: Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74: Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment: performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost. 2002;88: Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus. 2002;11: Harris EN. Special report: the Second International Anti-cardiolipin Standardization Workshop/ the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol. 1990;94: Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3: Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2- glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost. 2005;3: Audrain MA, El-Kouri D, Hamidou MA, et al. Value of autoantibodies to beta(2)-glycoprotein 1 in the diagnosis of antiphospholipid syndrome. Rheumatology (Oxford). 2002;41: The APASS Writing Committee. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004; 291: Schulman S, Svenungsson E, Granqvist S; Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104: Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZJMed. 1990;20: Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72: Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;161: Tsapanos V, Kanellopoulos N, Cardamakis E, et al. Anticardiolipin antibodies levels in healthy pregnant and non-pregnant woman. Arch Gynecol Obstet. 2000;263: Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86: Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997;77: Finazzi G. The Italian registry of antiphospholipid antibodies. Haematologica. 1997;82: Wahl DG, Guillemin F, de Maistre E, Perret- Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998; 7: Janardhan V, Wolf PA, Kase CS, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke. 2004;35: Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996;87: Rai RS, Clifford K, Cohen H, Regan L. High pro JAMA, March 1, 2006 Vol 295, No. 9 (Reprinted) 2006 American Medical Association. All rights reserved.

8 spective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995;10: Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80: Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992;167: Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997; 337: Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996;25: Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol. 1993;100: Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome: a prospective study. Ann Intern Med. 1994;120: Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86: Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001;44: Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151: Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II: optimal anticoagulant therapy for thrombosis. Thromb Res. 2005; 115: Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340: Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349: Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117: Khamashta MA, Cuadrado MJ, Mujic F, Taub MA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. NEngl J Med. 1995;332: Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100: Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. NEnglJMed. 2003; 349: Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005; 3: Erkan D, Bateman H, Lockshin MD. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus. 1999;8: Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46: Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):401s-428s. 58. Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005; 294: Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27: Tenedios F, Erkan D, Lockshin MD. Cardiac involvement in the antiphospholipid syndrome. Lupus. 2005;14: Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345: Brey RL, Chapman J, Levine SR, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina Lupus. 2003;12: Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;(2):CD Kutteh WH. Antiphospholipid antibodyassociated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174: Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314: Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002; 100: Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol. 1997; 176: Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? a randomized controlled trial. Am J Obstet Gynecol. 2000;183: Tulppala M, Marttunen M, Soderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod. 1997;12: Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003;12: Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12: Dentali F, Manfredi E, Crowther M, Ageno W. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost. 2005;3: Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12: Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2: Erkan D, Yazici Y, Harrison MJ, Peterson M, Sammaritano L, Lockshin MD. APLASA study: primary thrombosis prevention in asymptomatic antiphospholipid antibody (APL) patients with low-dose aspirin (ASA) [abstract]. Lupus. 2002;11:573a. 76. Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun. 2000;15: American Medical Association. All rights reserved. (Reprinted) JAMA, March 1, 2006 Vol 295, No

Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria

Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic

More information

Anti β 2. -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome

Anti β 2. -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome Coagulation and Transfusion Medicine / PREDICTIVE VALUE OF ANTIPHOSPHOLIPID ANTIBODIES Anti β -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With

More information

Clinical consequences of antiphospholipid antibodies

Clinical consequences of antiphospholipid antibodies Clinical consequences of antiphospholipid antibodies R.H.W.M. Derksen 1*, P.G. de Groot 2,3 1 Department of Rheumatology and Clinical Immunology, Room F02.127, 2 Thrombosis and Haemostasis Laboratory,

More information

Warfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time

Warfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time Clin. Lab. 2009;55:XXX-XXX Copyright ORIGINAL ARTICLE Warfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time HORATIU OLTEANU 2, KATHARINE. A. DOWNES 1, JIGAR

More information

Antiphospholipid antibodies

Antiphospholipid antibodies CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE Antiphospholipid Antibodies Caron P. Misita, PharmD; Stephan Moll, MD Antiphospholipid antibodies (APLAs) are proteins that may be present in the blood and

More information

Antiphospholipid antibodies and thrombosis: strength of association

Antiphospholipid antibodies and thrombosis: strength of association (2003) 4, 180 186 & 2003 The European Hematology Association All rights reserved 1466-4680/03 $25.00 www.nature.com/thj REVIEW Antiphospholipid antibodies and thrombosis: strength of association Monica

More information

A Case of Antiphospholipid Syndrome Refractory to Secondary Anticoagulating Prophylaxis after Deep Vein Thrombosis- Pulmonary Embolism

A Case of Antiphospholipid Syndrome Refractory to Secondary Anticoagulating Prophylaxis after Deep Vein Thrombosis- Pulmonary Embolism CASE REPORT http://dx.doi.org/10.4046/trd.2014.77.6.274 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2014;77:274-278 A Case of Antiphospholipid Syndrome Refractory to Secondary Anticoagulating

More information

Current View of the Treatment of Antiphospholipid Syndrome

Current View of the Treatment of Antiphospholipid Syndrome GROUPE HOSPITALIER PITIE SALPETRIERE Current View of the Treatment of Antiphospholipid Syndrome Pr Zahir AMOURA Department of Internal Medicine French National Reference center for SLE and APS Hôpital

More information

Lupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid

Lupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid , Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update William L. Nichols, MD Mayo Clinic College of Medicine Rochester, Minnesota USA Disclosures & Objectives (Nichols) Disclosures Relevant

More information

Antiphospholipid syndrome: treatment controversies

Antiphospholipid syndrome: treatment controversies REVIEW Antiphospholipid syndrome: treatment controversies Guillermo Ruiz- Irastorza & Munther A Khamashta Author for correspondence St Thomas Hospital, Lupus Research Unit, The Rayne Institute, London,

More information

T he antiphospholipid syndrome (APS) is a thrombophilic

T he antiphospholipid syndrome (APS) is a thrombophilic 1639 EXTENDED REPORT ntiphospholipid antibody tests: spreading the net M L ertolaccini, S Gomez, J F P Pareja, Theodoridou, G Sanna, G R V Hughes, M Khamashta... See end of article for authors affiliations...

More information

Lupus anticoagulant and anticardiolipin antibodies in SLE with secondary Antiphospholipid Antibody Syndrome

Lupus anticoagulant and anticardiolipin antibodies in SLE with secondary Antiphospholipid Antibody Syndrome Turk J Hematol 2007; 24:69-74 Turkish Society of Hematology RESEARCH ARTICLE Lupus anticoagulant and anticardiolipin antibodies in SLE with secondary Antiphospholipid Antibody Syndrome Shveta Garg, Annamma

More information

Sindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy

Sindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy Sindrome da anticorpi antifosfolipidi: clinica e terapia Vittorio Pengo Clinical Cardiology, Padova, Italy Revised Classification Criteria for the Antiphospholipid Syndrome J Thromb Haemost 2006;4:295-306

More information

Key words: antiphospholipid syndrome, trombosis, pathogenesis

Key words: antiphospholipid syndrome, trombosis, pathogenesis 26. XI,. 4/2011,.,..,..,., -..,,. 2GPI. -,.,,., -,, -, -,,,,, IL-1, IL-2, IL-6, IL-8, IL-12, IL-10, TNF, INF-. :,, N. Stoilov, R. Rashkov and R. Stoilov. ANTIPHOSPHOLIPID SYNDROME HISTORICAL DATA, ETI-

More information

Prevalence of antiphospholipid auto antibodies in patients with thrombosis

Prevalence of antiphospholipid auto antibodies in patients with thrombosis EUROPEAN ACADEMIC RESEARCH Vol. IV, Issue 6/ September 2016 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Prevalence of antiphospholipid auto antibodies in patients

More information

Antiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis?

Antiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis? Rheum Dis Clin N Am 32 (2006) 455 463 Antiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis? Maria Laura Bertolaccini, MD, PhD*, Graham R.V. Hughes, MD, FRCP Lupus Research Unit, The Rayne

More information

Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist

Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March

More information

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness

More information

Are there still any valid indications for thrombophilia screening in DVT?

Are there still any valid indications for thrombophilia screening in DVT? Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016

More information

APPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL

APPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH

More information

Thrombophilia: To test or not to test

Thrombophilia: To test or not to test Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical

More information

DOACs in SPECIAL POPULATIONS

DOACs in SPECIAL POPULATIONS DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy

More information

THE antiphospholipid-antibody syndrome is a

THE antiphospholipid-antibody syndrome is a Vol. 332. 15 MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME 993 THE MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME MUNTHER A. KHAMASHTA, M.D., MARIA JOSE CUADRADO,

More information

Available Online at CODEN: IJRSFP (USA) Vol. 9, Issue, 3(L), pp , March, 2018.

Available Online at  CODEN: IJRSFP (USA) Vol. 9, Issue, 3(L), pp , March, 2018. ISSN: 0976-3031 Available Online at http://www.recentscientific.com CODEN: IJRSFP (USA) International Journal of Recent Scientific Research Vol. 9, Issue, 3(L), pp. 25504-25508, March, 2018 Research Article

More information

Primary Care practice clinics within the Edmonton Southside Primary Care Network.

Primary Care practice clinics within the Edmonton Southside Primary Care Network. INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized

More information

Antiphospholipid Syndrome ( APS)

Antiphospholipid Syndrome ( APS) Antiphospholipid Syndrome ( APS) Edward John Walter Bowie, MD Mayo Medical School the first to identify APS as an acquired thrombophilia Graham Robert Vivian Hughes MD FRCP Unit Rayne Institute St Thomas

More information

Daniel Egan, MD April 13, 2012

Daniel Egan, MD April 13, 2012 Daniel Egan, MD April 13, 2012 Aug 2006 (at age 15): Acute unprovoked DVT in left common femoral vein Factor V Leiden heterozygous Positive lupus inhibitor Lovenox BID 2 weeks later: increased clot burden,

More information

Mortality in the Catastrophic Antiphospholipid Syndrome

Mortality in the Catastrophic Antiphospholipid Syndrome ARTHRITIS & RHEUMATISM Vol. 54, No. 8, August 2006, pp 2568 2576 DOI 10.1002/art.22018 2006, American College of Rheumatology Mortality in the Catastrophic Antiphospholipid Syndrome Causes of Death and

More information

Summary of the 11th International Congress on Antiphospholipid Antibodies, Sydney, Australia, November 2004

Summary of the 11th International Congress on Antiphospholipid Antibodies, Sydney, Australia, November 2004 Journal of Reproductive Immunology 66 (2005) 85 90 Meeting report Summary of the 11th International Congress on Antiphospholipid Antibodies, Sydney, Australia, November 2004 The 11th International Congress

More information

The Antiphospholipid Syndrome

The Antiphospholipid Syndrome The Antiphospholipid Syndrome 1 / 6 2 / 6 3 / 6 The Antiphospholipid Syndrome Antiphospholipid antibody syndrome (commonly called antiphospholipid syndrome or APS) is an autoimmune disease present mostly

More information

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is

More information

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:

More information

Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS

Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis

More information

Anticardiolipin Antibodies in Patients With Type 2 Diabetes Mellitus

Anticardiolipin Antibodies in Patients With Type 2 Diabetes Mellitus CM&R Rapid Release. Published online ahead of print February 26, 2009 as doi:10.3121/cmr.2008.828 Original Research Anticardiolipin Antibodies in Patients With Type 2 Diabetes Mellitus José María Calvo-Romero,

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone

More information

Introduction. Patients, materials, and methods

Introduction. Patients, materials, and methods HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

More information

In the Clinic: Annals Sweta Kakaraparthi 1/23/15

In the Clinic: Annals Sweta Kakaraparthi 1/23/15 In the Clinic: Annals Sweta Kakaraparthi 1/23/15 Case Scenerio 56 year old female with breast cancer presents to the clinic for her 3 month followup! She is concerned about blood clots and asks you about

More information

Evaluation of antiphospholipid antibodies testing for the diagnosis of antiphospholipid syndrome

Evaluation of antiphospholipid antibodies testing for the diagnosis of antiphospholipid syndrome Original Article Evaluation of antiphospholipid antibodies testing for the diagnosis of antiphospholipid syndrome Paula Gonçalves Perches¹, Daniela Pezzutti Domingues¹, Andréia Latanza Gomes², Augusta

More information

The management of venous thromboembolism has improved. Article

The management of venous thromboembolism has improved. Article Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism A Randomized, Double-Blind, Controlled Trial

More information

Mohammadreza Tabatabaei IBTO COAG LAB

Mohammadreza Tabatabaei IBTO COAG LAB Tests for the Evaluation of Lupus Anticoagulants t Mohammadreza Tabatabaei MSc Hematology blood bank MSc Hematology blood bank IBTO COAG LAB Lupus Anticoagulants General Background Lupus anticoagulants

More information

Updates in Diagnosis & Management of VTE

Updates in Diagnosis & Management of VTE Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE

More information

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from

More information

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE

More information

Guidelines. 704 q 2000 Blackwell Science Ltd GUIDELINES ON THE INVESTIGATION AND MANAGEMENT OF THE ANTIPHOSPHOLIPID SYNDROME

Guidelines. 704 q 2000 Blackwell Science Ltd GUIDELINES ON THE INVESTIGATION AND MANAGEMENT OF THE ANTIPHOSPHOLIPID SYNDROME British Journal of Haematology 2000, 109, 704±715 Guidelines GUIDELINES ON THE INVESTIGATION AND MANAGEMENT OF THE ANTIPHOSPHOLIPID SYNDROME In 1991, the Haemostasis and Thrombosis Task Force of the British

More information

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy: Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division

More information

criterion (positive lupus anticoagulant or

criterion (positive lupus anticoagulant or FERTILITY AND STERILITY Vol. 66, No.4, October 1996 Copyright 1996 American Society for Reproductive Medicine Printed on acid~free paper in U. s. A. Antiphospholipid antibody panels and recurrent pregnancy

More information

2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss

2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss FERTILITY AND STERILITY VOL. 73, NO. 3, MARCH 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. 2-Glycoprotein 1 as

More information

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew

More information

The antiphospholipid syndrome: still an enigma

The antiphospholipid syndrome: still an enigma CHALLENGING SCENARIOS IN THROMBOSIS The antiphospholipid syndrome: still an enigma Shruti Chaturvedi 1 and Keith R. McCrae 2 1 Division of Hematology, Vanderbilt University Medical Center, Nashville, TN;

More information

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?

More information

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following

More information

Original Policy Date

Original Policy Date MP 2.04.71 Genetic Testing for Inherited Thrombophilia Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search12:2013 Return to

More information

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be

More information

Deep vein thrombosis (DVT) is a pervasive LOW-MOLECULAR-WEIGHT HEPARIN IN THE TREATMENT OF ACUTE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM *

Deep vein thrombosis (DVT) is a pervasive LOW-MOLECULAR-WEIGHT HEPARIN IN THE TREATMENT OF ACUTE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM * LOW-MOLECULAR-WEIGHT HEPARIN IN THE TREATMENT OF ACUTE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM * Geno J. Merli, MD ABSTRACT There are more than 170 000 hospital admissions each year for deep vein thrombosis

More information

Title. CitationLupus, 21(14): Issue Date Doc URL. Rights. Type. File Information

Title. CitationLupus, 21(14): Issue Date Doc URL. Rights. Type. File Information Title Predominant prevalence of arterial thrombosis in Jap Fujieda, Yuichiro; Atsumi, Tatsuya; Amengual, Olga; Author(s) Yujiro; Horita, Tetsuya; Yasuda, Shinsuke; Koike, Ta CitationLupus, 21(14): 1506-1514

More information

Duration of Therapy for Venous Thromboembolism

Duration of Therapy for Venous Thromboembolism Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee

More information

Autoantibodies have been implicated in a variety of diseases.

Autoantibodies have been implicated in a variety of diseases. Antiphospholipid Antibodies Douglas A. Triplett, MD Objective. To review the role of lupus anticoagulants in the pathogenesis of both venous and arterial thromboembolic events, as well as in recurrent

More information

AN INTERESTING CASE OF RESPIRATORY DISTRESS. Dr.V.Akila Devi DNB PG Southern Railway Headquarters Hospital Chennai

AN INTERESTING CASE OF RESPIRATORY DISTRESS. Dr.V.Akila Devi DNB PG Southern Railway Headquarters Hospital Chennai AN INTERESTING CASE OF RESPIRATORY DISTRESS Dr.V.Akila Devi DNB PG Southern Railway Headquarters Hospital Chennai 11 month old female infant 1 st born to parents of NC marriage referred from Kolkatta H/O:

More information

DOWNLOAD OR READ : POSITIVE OPTIONS FOR ANTIPHOSPHOLIPID SYNDROME APS SELF HELP AND TREATMENT PDF EBOOK EPUB MOBI

DOWNLOAD OR READ : POSITIVE OPTIONS FOR ANTIPHOSPHOLIPID SYNDROME APS SELF HELP AND TREATMENT PDF EBOOK EPUB MOBI DOWNLOAD OR READ : POSITIVE OPTIONS FOR ANTIPHOSPHOLIPID SYNDROME APS SELF HELP AND TREATMENT PDF EBOOK EPUB MOBI Page 1 Page 2 positive options for antiphospholipid syndrome aps self help and treatment

More information

REVIEW ARTICLE. Antiphospholipid syndrome

REVIEW ARTICLE. Antiphospholipid syndrome REVIEW ARTICLE 336 Antiphospholipid syndrome Sanjay C Keswani BSc MRCP Naresh Chauhan MRCP 1 J R Soc Med 2002;95:336 342 The antiphospholipid syndrome (APS) is characterized by thrombosis, recurrent fetal

More information

Thrombotic Risk Factors In Primary Antiphospholipid Syndrome A 5-Year Prospective Study

Thrombotic Risk Factors In Primary Antiphospholipid Syndrome A 5-Year Prospective Study Thrombotic Risk Factors In Primary Antiphospholipid Syndrome A 5-Year Prospective Study Maurizio Turiel, MD; Piercarlo Sarzi-Puttini, MD; Rossana Peretti, MD; Edoardo Rossi, MD; Fabiola Atzeni, MD; Wendy

More information

Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)

Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h) Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase

More information

Keywords: apl, Hughes syndrome, pregnancy loss, prothrombin, thrombosis. Introduction

Keywords: apl, Hughes syndrome, pregnancy loss, prothrombin, thrombosis. Introduction Journal of Thrombosis and Haemostasis, 10: 2512 2518 DOI: 10.1111/jth.12014 ORIGINAL ARTICLE Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of

More information

PD Dr. med. habil. Michaela Jaksch, Consultant Laboratory Medicine, Medical Director, Freiburg Medical Laboratory ME LLC, Dubai, UAE

PD Dr. med. habil. Michaela Jaksch, Consultant Laboratory Medicine, Medical Director, Freiburg Medical Laboratory ME LLC, Dubai, UAE Autoimmune Disorders in Gynecology/Obstetrics PD Dr. med. habil. Michaela Jaksch, Consultant Laboratory Medicine, Medical Director, Freiburg Medical Laboratory ME LLC, Dubai, UAE Abstract The spectrum

More information

Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press)

Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press) Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN 0140-6736 (In Press) Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/1087/1/lancet_clots_1_20090522_4.pdf

More information

ORIGINAL PAPERS. Marek Cieśla 1, B D, Ewa Wypasek 1, 2, B D 1, 2, A, E, F. Abstract

ORIGINAL PAPERS. Marek Cieśla 1, B D, Ewa Wypasek 1, 2, B D 1, 2, A, E, F. Abstract ORIGINAL PAPERS Adv Clin Exp Med 2014, 23, 5, 729 733 ISSN 1899 5276 Copyright by Wroclaw Medical University Marek Cieśla 1, B D, Ewa Wypasek 1, 2, B D 1, 2, A, E, F, Anetta Undas IgA Antiphospholipid

More information

Sang Hyuk Park, 1,2 Seongsoo Jang, 3 Chan-Jeoung Park, 3 and Hyun-Sook Chi Introduction

Sang Hyuk Park, 1,2 Seongsoo Jang, 3 Chan-Jeoung Park, 3 and Hyun-Sook Chi Introduction BioMed Research International Volume 2016, Article ID 2641526, 6 pages http://dx.doi.org/10.1155/2016/2641526 Research Article Clinical Application of Revised Laboratory Classification Criteria for Antiphospholipid

More information

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri

More information

Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism

Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism

More information

TECHNICAL SERIES. Lupus Anticoagulants: Basic Concepts and Laboratory Diagnosiss. ...Setting trends TULIP DIAGNOSTICS (P) LTD.

TECHNICAL SERIES. Lupus Anticoagulants: Basic Concepts and Laboratory Diagnosiss. ...Setting trends TULIP DIAGNOSTICS (P) LTD. For the use of Registered Medical Practioners and Laboratories only TECHNICAL SERIES Lupus Anticoagulants: Basic Concepts and Laboratory Diagnosiss TULIP DIAGNOSTICS (P) LTD. Gitanjali, Tulip Block, Dr.

More information

NeuroPI Case Study: Anticoagulant Therapy

NeuroPI Case Study: Anticoagulant Therapy Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination

More information

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events. ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

More information

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)

More information

Review Article. The antiphospholipid syndrome RAHUL GROVER, ASHOK KUMAR

Review Article. The antiphospholipid syndrome RAHUL GROVER, ASHOK KUMAR GROVER, THE NATIONAL KUMAR MEDICAL : THE ANTIPHOSPHOLIPID JOURNAL OF INDIA SYNDROME VOL. 16, NO. 6, 2003 Review Article 311 The antiphospholipid syndrome RAHUL GROVER, ASHOK KUMAR ABSTRACT The antiphospholipid

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle  holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue

More information

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular

More information

Apixaban for stroke prevention in atrial fibrillation. August 2010

Apixaban for stroke prevention in atrial fibrillation. August 2010 Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Extended Use of Da bi gat ran, Warfarin, or Placebo in Venous Thromboembolism

Extended Use of Da bi gat ran, Warfarin, or Placebo in Venous Thromboembolism T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Extended Use of,, or Placebo in Venous Thromboembolism Sam Schulman, M.D., Ph.D., Clive Kearon, M.D., Ajay K. Kakkar, M.B., B.S.,

More information

Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism

Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.

More information

All about Antiphospholipid Syndrome. M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India

All about Antiphospholipid Syndrome. M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India All about Antiphospholipid Syndrome M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India 1 2 3 4 5 6 Antiphospholipid syndrome A study of 192

More information

Antiphospholipid Syndrome

Antiphospholipid Syndrome Antiphospholipid Syndrome EliA Cardiolipin and EliA β2-glycoprotein I Fully Automated Testing for Antiphospholipid Syndrome (APS) Testing for APS according to classification criteria determination of anti-β2-glycoprotein

More information

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical

More information

46 Antiphospholipid Syndrome

46 Antiphospholipid Syndrome 46 Antiphospholipid Syndrome Abstract: Antiphospholipid antibodies (apl) are a family of autoantibodies directed against phospholipids, phospholipid-binding proteins or both having a broad range of target

More information

Menopausal Hormone Therapy & Haemostasis

Menopausal Hormone Therapy & Haemostasis Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen

More information

Anaesthesiologic management of a parturient with a known antiphospholipid syndrome

Anaesthesiologic management of a parturient with a known antiphospholipid syndrome Anaesthesiologic management of a parturient with a known antiphospholipid syndrome Pascal Vuilleumier Universitätsklinik für Anästhesie und Schmerztherapie Case presentation: Mrs A. B. 1975 Early monday

More information

Chapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy

Chapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy Chapter Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy Willem M. Lijfering Min Ki ten Kate Herman G. Sprenger Jan van der Meer

More information

Clinical Investigation and Reports

Clinical Investigation and Reports Clinical Investigation and Reports Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin Sonia S. Anand, MD,

More information

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date: Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Chapter 1. Introduction

Chapter 1. Introduction Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150

More information

Dental Management Considerations for Patients on Antithrombotic Therapy

Dental Management Considerations for Patients on Antithrombotic Therapy Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine

More information

Generate Knowledge Lupus Anticoagulant Testing Made Simple

Generate Knowledge Lupus Anticoagulant Testing Made Simple Generate Knowledge Lupus Anticoagulant Testing Made Simple Paul Riley, PhD, MBA Learning objectives Describe antiphospholipid syndrome (aps) and role of the lupus anticoagulant (LA) in thrombosis Present

More information

Results from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine

Results from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine Press Release Daiichi Sankyo s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE

More information

MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC

MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal

More information

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management

More information

Antiphospholipid antibodies in patients with venous thrombosis at Kenyatta National Hospital

Antiphospholipid antibodies in patients with venous thrombosis at Kenyatta National Hospital Research article Department of Human Pathology, School of Medicine, University of Nairobi, P. O. Box 19676 00202, Nairobi, Kenya Corresponding author: Dr KA Barasa, Department of Human Pathology, School

More information

Review Low-molecular-weight heparins in the treatment of venous thromboembolism Walter Ageno and Menno V Huisman*

Review Low-molecular-weight heparins in the treatment of venous thromboembolism Walter Ageno and Menno V Huisman* Review Low-molecular-weight heparins in the treatment of venous thromboembolism Walter Ageno and Menno V Huisman* University of Insubria, Varese, Italy, and *Leiden University Medical Centre, Leiden, The

More information

Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)

Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome) Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome) Ara Metjian, MD Duke Debates Benign Hematologic Highlights April 22, 2017 Disclaimer

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

Venous thromboembolism (VTe) affects approximately

Venous thromboembolism (VTe) affects approximately The Journal of The american osteopathic association Duration of Anticoagulation Treatment in Patients With Venous Thromboembolism Scott Kaatz, DO, MSc; Waqas Qureshi, MD; Christopher Fain, DO; and David

More information